Literature DB >> 15105151

In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.

S A Kohlhoff1, P M Roblin, T Reznik, S Hawser, K Islam, M R Hammerschlag.   

Abstract

The in vitro activities of iclaprim, a novel dihydrofolate reductase inhibitor, azithromycin, and levofloxacin were tested against 10 strains of Chlamydia trachomatis and 10 isolates of Chlamydia pneumoniae. For C. trachomatis and C. pneumoniae, the iclaprim MIC and minimal bactericidal concentration at which 90% of isolates were inhibited (MIC(90) and MBC(90)) were 0.5 micro g/ml, compared to an azithromycin MIC(90) and MBC(90) of 0.125 micro g/ml and levofloxacin MIC(90)s and MBC(90)s of 1 micro g/ml for C. trachomatis and 0.5 micro g/ml for C. pneumoniae.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105151      PMCID： PMC400585          DOI： 10.1128/AAC.48.5.1885-1886.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Tamara Reznik; Margaret R Hammerschlag
Journal:  Int J Antimicrob Agents       Date:  2003-06       Impact factor: 5.283

2.  Activity of trimethoprim-sulfamethoxazole against Chlamydia trachomatis in vitro.

Authors:  M R Hammerschlag
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

3.  Acquisition and synthesis of folates by obligate intracellular bacteria of the genus Chlamydia.

Authors:  H Fan; R C Brunham; G McClarty
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808
  3 in total
  7 in total

Review 1.  Antibiotic resistance in Chlamydiae.

Authors:  Kelsi M Sandoz; Daniel D Rockey
Journal:  Future Microbiol       Date:  2010-09       Impact factor: 3.165

2.  In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.

Authors:  George G Zhanel; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

3.  Randomized, double-blind, multicenter safety and efficacy study of rifalazil compared with azithromycin for treatment of uncomplicated genital Chlamydia trachomatis infection in women.

Authors:  William M Geisler; Maria Luz G Pascual; Judy Mathew; William D Koltun; Franklin Morgan; Byron E Batteiger; Annette Mayes; Sijia Tao; Selwyn J Hurwitz; Chalom Sayada; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 4.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

Review 6.  Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

Authors:  Vanessa R Anderson; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy.

Authors:  Ayman M Noreddin; Walid F Elkhatib; Kenji M Cunnion; George G Zhanel
Journal:  Drug Healthc Patient Saf       Date:  2011-10-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.